FDA-AACR Workshop to Address Multiple Myeloma Clinical Trial Disparities
By Trevan Locke, PhD Thanks to a wave of newly approved therapies in the past two decades, survival rates...
Year: 2020: 2020
By Trevan Locke, PhD Thanks to a wave of newly approved therapies in the past two decades, survival rates...
Despite considerable progress against cancer, the disease continues to take a huge toll on global health. Each year, approximately...
While there have been great strides in lowering the incidence and mortality rates of cervical cancer in the United...
Back for the new decade is our regular staple: the monthly collection of 10 “must read” articles that have...
The first new anticancer therapeutics approved by the U.S. Food and Drug Administration (FDA) in 2020 are for the...
The advent of immunotherapy has led to durable responses for an increasing number of patients, including many who initially...
The first paper to be accepted by the AACR’s latest journal, Blood Cancer Discovery, was published online last week....
The U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called fam-trastuzumab deruxtecan-nxki (Enhertu) for treating...
The new year began with the good news that death rates from cancer are continuing their steady decline. A...
Around 400 BC, the Greek physician Hippocrates is believed to have first described tumors as “cancer,” using the words...